Loading
Heart Failure Treatment and Management · Journal article
Esc Heart Failure · August 8, 2026
Well-designed and adequately powered for the question it asks.
This secondary analysis of a prospectively phenotyped HFpEF/HFmrEF cohort with invasive hemodynamics demonstrates that type 2 diabetes is independently associated with adverse myocardial remodeling (greater left ventricular mass, lower ejection fraction, impaired strain, elevated filling pressures) and doubled risk of heart failure events or cardiovascular death over 4 years, after adjustment for body mass index and other covariates. The finding indicates that T2DM confers metabolic burden to the myocardium independent of obesity.
Secondary analysis of prospectively phenotyped sham-control cohort from randomized trial. Patients with HFpEF or HFmrEF enrolled in the sham-control arm of REDUCE LAP-HF II trial, prospectively phenotyped and undergoing invasive hemodynamic assessment.. Intervention: Type 2 diabetes status (observational grouping). Compared with: Non-T2DM patients, with adjustment for body mass index and clinical covariates. n = 312.
T2DM present in 37% of patients and independently associated with increased risk of HF events or CV death (adjusted HR 1.96, 95% CI 1.28-3.00) After BMI adjustment, T2DM remained independently associated with greater left ventricular mass, lower ejection fraction, impaired left ventricular global longitudinal strain, and reduced right ventricular free-wall strain Median follow-up 4.0 years (interquartile range 2.5-5.0); outcomes driven by heart failure events
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that in HFpEF/HFmrEF patients, type 2 diabetes independently portends worse structural remodeling, hemodynamic derangement, and clinical outcomes beyond the effects of obesity alone, potentially warranting more aggressive metabolic management in this population. The doubling of heart failure event risk supports intensive T2DM control as part of HFpEF/HFmrEF management strategy.
Rigorous secondary analysis of a prospectively phenotyped cohort with invasive hemodynamic assessment, multivariable adjustment, and hard clinical endpoints over 4-year follow-up demonstrates T2DM's independent association with adverse cardiac remodeling and clinical outcomes in HFpEF/HFmrEF.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that in HFpEF/HFmrEF patients, type 2 diabetes independently portends worse structural remodeling, hemodynamic derangement, and clinical outcomes beyond the effects of obesity alone, potentially warranting more aggressive metabolic management in this population. The doubling of heart failure event risk supports intensive T2DM control as part of HFpEF/HFmrEF management strategy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Type 2 diabetes mellitus (T2DM) and obesity are the archetypal components of cardiometabolic syndromes associated with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). The specific contribution of T2DM, independent of obesity, to myocardial adaptations and outcomes remains uncertain. OBJECTIVES: We aimed to explore the obesity-independent contribution of T2DM to cardiac structure, function, central hemodynamics, and outcomes. METHODS: We leveraged the sham-control arm of the REDUCE LAP-HF II trial (n=312), a prospectively phenotyped cohort of patients with HFpEF/HFmrEF undergoing invasive hemodynamic assessment. Multivariable models were used to adjust for body mass index (BMI) and clinical covariates. Outcomes included cardiovascular death, and total heart failure events. RESULTS: T2DM was present in 37% of patients and was associated with higher BMI, chronic kidney disease, and prior heart failure hospitalization. Obesity was present in 62% of patients and was more prevalent in those with T2DM (70% vs 57%, p=0.032). After adjustment for BMI, T2DM remained independently associated with greater left ventricular mass, lower ejection fraction, impaired left ventricular global longitudinal strain, reduced right ventricular free-wall strain, and higher resting filling pressures. Over a median 4.0 year (2.5-5.0) follow-up, T2DM was independently associated with increased risk of HF events or CV death (adjusted HR 1.96, 95% CI 1.28-3.00), driven by heart failure events, whereas BMI was not independently prognostic. CONCLUSIONS: HFpEF/HFmrEF patients with T2DM experience adverse myocardial remodeling, impaired biventricular function, adverse central hemodynamics, and worse clinical outcomes independent of obesity. These findings indicate that T2DM confers additional metabolic burden to the myocardium, beyond that attributable to obesity alone.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.